HALO
Halozyme Therapeutics Inc.

4,886
Mkt Cap
$9.55B
Volume
2.25M
52W High
$81.36
52W Low
$47.50
PE Ratio
17.07
HALO Fundamentals
Price
$81.33
Prev Close
$78.42
Open
$79.01
50D MA
$69.63
Beta
0.71
Avg. Volume
1.88M
EPS (Annual)
$3.43
P/B
18.94
Rev/Employee
$2.9M
Loading...
Loading...
News
all
press releases
New York State Common Retirement Fund Sells 3,399,839 Shares of Halozyme Therapeutics, Inc. $HALO
New York State Common Retirement Fund decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 98.2% during the third quarter, according to the company in its most recent...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Renaissance Group LLC Invests $35.11 Million in Halozyme Therapeutics, Inc. $HALO
Renaissance Group LLC purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the third quarter, according to its most recent disclosure with the SEC. The institutional...
MarketBeat·1d ago
News Placeholder
Halozyme Therapeutics (NASDAQ:HALO) Hits New 12-Month High - Time to Buy?
Halozyme Therapeutics (NASDAQ:HALO) Sets New 52-Week High - Time to Buy...
MarketBeat·2d ago
News Placeholder
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 10,000 Shares of Stock
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 10,000 shares of the business's stock in a transaction dated Thursday, February 5th. The shares were sold at an...
MarketBeat·2d ago
News Placeholder
Halozyme Therapeutics, Inc. $HALO Shares Acquired by Thrivent Financial for Lutherans
Thrivent Financial for Lutherans increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 222.5% in the third quarter, according to the company in its most recent disclosure...
MarketBeat·2d ago
News Placeholder
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 10,000 Shares
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 10,000 shares of the business's stock in a transaction on Thursday, February 5th. The shares were sold at an average...
MarketBeat·3d ago
News Placeholder
Helen Torley Sells 20,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the business's stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at...
MarketBeat·3d ago
News Placeholder
BI Asset Management Fondsmaeglerselskab A S Sells 155,995 Shares of Halozyme Therapeutics, Inc. $HALO
BI Asset Management Fondsmaeglerselskab A S lowered its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 35.1% during the 3rd quarter, according to the company in its most...
MarketBeat·3d ago
News Placeholder
Hantz Financial Services Inc. Has $7.18 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO
Hantz Financial Services Inc. decreased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 27.3% in the third quarter, according to the company in its most recent...
MarketBeat·3d ago
News Placeholder
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·4d ago
<
1
2
...
>

Latest HALO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.